Skip to main content
. 2022 Sep 5;10(9):2194. doi: 10.3390/biomedicines10092194

Figure 4.

Figure 4

Any thrombotic events in different dosing regimens in moderate and severe disease cohorts [19,20,21,22,23,24,25,51,52,53,54,55,56]. (A) Any thrombotic events in severe and moderate disease cohorts; (B) any thrombotic events in cohorts where an intermediate or therapeutic dose was used in the HD group.